Non-clinical safety considerations on genome editing using the CRISPR/Cas system

Area of Science:

• Molecular Biology
• Biotechnology
• Genetics

Background:

• CRISPR-Cas technology has significantly advanced genome editing capabilities.
• Gene editing is increasingly utilized in clinical trials for therapeutic applications.
• Translating research findings into clinical practice necessitates rigorous safety evaluations.

Purpose of the Study:

• To review current CRISPR-Cas gene editing approaches (ex vivo and in vivo).
• To discuss the application of these methods in pre-clinical studies and clinical settings.
• To highlight non-clinical safety considerations for translating gene editing to the clinic.

Main Methods:

• Literature review of CRISPR-Cas gene editing techniques.
• Analysis of current pre-clinical and clinical applications.
• Discussion of safety factors and risk mitigation strategies.

Main Results:

• CRISPR-Cas system offers revolutionary potential for human cellular and gene therapy.
• Clinical adoption of genome editing technologies is accelerating.
• Critical non-clinical safety assessments are essential for successful translation.

Conclusions:

• Safe translation of CRISPR-Cas gene editing to the clinic requires a thorough understanding of limitations and risks.
• Addressing safety concerns is paramount for developing effective gene therapy products.
• This review provides a perspective crucial for researchers navigating the clinical translation of genome editing.